HELP YOUR PATIENTS WITH MIGRAINE SAVE ON REYVOW

Eligible, commercially insured patients can pay as little as $0 for up to 12 months with the REYVOW Savings Card^*

^*Depending on patient coverage.

Savings in just a few simple steps:

^aPatients need PA approved by second fill and insurance must continue to cover the claim for patients to pay as little as $0 for up to 12 months.
Please work with the patient's plan to pursue claim approval by the second fill. Patients need approval by second fill to continue to pay as little as $0 for REYVOW.

^*Terms and Conditions:

Subject to Lilly USA, LLC’s (Lilly’s) right to terminate, rescind, revoke or amend the Reyvow Savings Card Program (“Card”) eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025. Card savings are not available to patients without commercial drug insurance or who are enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program.

MONTHLY AND ANNUAL MAXIMUM SAVINGS: For patients with commercial drug insurance coverage for Reyvow: You must have commercial drug insurance that covers Reyvow^® (lasmiditan) and a prescription for an approved use consistent with FDA- approved product labeling to pay as little as $0 for a 1-month prescription fill of Reyvow. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $3,400 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.

For patients with commercial drug insurance who do not have coverage for Reyvow: You must have commercial drug insurance that does not cover Reyvow and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $0 for your first 1-month prescription fill of Reyvow. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges for one 30-day supply of Reyvow. Card may be used for a maximum of 1 prescription fill. Subject to Lilly’s right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.

ADDITIONAL TERMS AND CONDITIONS:
You are responsible for any applicable taxes, fees and any amount that exceeds the monthly or annual maximum benefits. Savings card activation is required. This Card may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Subject to additional terms and conditions. Eligibility criteria and terms and conditions for the Reyvow Savings Card Program may change from time to time at Lilly’s sole discretion and for any reason; the most current version can be found at https://reyvow.lilly.com/savings-support . Card benefits void where prohibited by law. THIS CARD IS NOT INSURANCE.

Your patients can text REY to 85099 to receive a guide to savings and information on taking REYVOW, including instructions for downloading the Savings Card directly on their phone.

Message and data rates apply.

Resources For Your Practice

Get access to helpful resources as you get your patients started with REYVOW

Prior Authorization Assistance

A quick guide to completing the REYVOW prior authorization request for you and your office staff.

Example Appeal Letter

A sample letter to appeal coverage determination or prior authorization for a patient’s plan.

Example Letter of Medical Necessity

A sample letter with Letter of Medical Necessity considerations.

Pharmacy Assistance

An overview for pharmacists that combines relevant product and savings information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Driving Impairment - REYVOW may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of REYVOW significantly impaired subjects’ ability to drive. Additionally, more sleepiness was reported at 8 hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.

Central Nervous System Depression - REYVOW may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for REYVOW to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after REYVOW is taken.

Serotonin Syndrome - In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with REYVOW who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with REYVOW during coadministration with serotonergic drugs e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (e.g., hyperreflexia, incoordination), and/or gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue REYVOW if serotonin syndrome is suspected.

Medication Overuse Headache - Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.

ADVERSE REACTIONS

The most common adverse reactions associated with REYVOW (≥2% and greater than placebo in clinical studies) were dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness.

ABUSE

REYVOW contains lasmiditan, a Schedule V controlled substance (C-V).
REYVOW has abuse potential. Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.

See Prescribing Information and Medication Guide.
LM HCP ISI 28SEP2020

INDICATIONS

REYVOW is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: REYVOW is not indicated for the preventive treatment of migraine.